10. 1. Amit, S., Regev-Yochay, G., & Afek, A. (2021). Early
rate reductions of SARS-Cov-2 infection and Covid-19
in BNT1626b2 vaccine recipients. Lancet, 397(10277),
875-877.
2. Baden, R.L., El Sahly, H.M., & Essink, B. (2021). Ef-
ficacy and safety of the mRNA-1273 SARS-Cov-2 vac-
cine. New England Journal of Medicine, 384(5), 403-416.
3. Barros-Martins, J., Hammerschmidt, S.I., & Cossmann,
A. (2021). Humoral and cellular immune response against
SARS-CoV-2 variants following heterologous and ho-
mologous
4. ChAdOx1 nCoV-19/BNT162b2 vaccination. medRxiv,
2021, https://doi.org/10.1101/2021.06.01.21258172
5. Callaway, E. (2021). Mixing Covid vaccines triggers
potent immune response. Nature, 593, 491.
6. Centers for Disease Control and Prevention. (2021).
Different Covid-19 vaccines. https://www.cdc.gov/coro-
navirus/2019-ncov/vaccines/different-vaccines.html
7. Coronavirus Vaccine Tracker (2021). The New York
Times. https://www.nytimes.com/interactive/2020/sci-
ence/coronavirus-vaccine-tracker.html. 2021 July 12;
Accessed: 15 July 2021.
8. Cirillo, N., & Doan, R. (2021). Bell´s palsy and SARS-
CoV-2 vaccines – an unfolding story. Lancet Infectious
Diseases, https://doi.org./10.1016/s1473-3099(21)00273-5
9. Dagan, N., Barda, N., & Kepten, E. (2021). BNT162b2
mRNA Covid-19 vaccine in a nationwide mass vaccina-
tion setting. New England Journal of Medicine, 384(15),
1412-1423.
10. Evans, S.J.W., & Jewell, N.P. (2021). Vaccine effec-
tiveness studies in the field. New England Journal of
Medicine, https://doi.org/10.1056/NEJMe2110605
11. Gray, K.J., Bordt, E.A., & Atyeo, C. (2021). Covid-19
vaccine response in pregnant and lactating women: A
cohort study. American Journal of Obstetrics and Gyne-
cology, https://doi.org/10.1016/j.ajog.2021.03.023
12. Hasan, T., Khan, M., & Khan, F. (2021). Case of Guil-
lain-Barre syndrome following Covid-19 vaccine. British
Medical Journal Case Report, 14, e243629, https://doi.
org/10.1136/bcr-2021-243629
13. Heller, J. (2021). Israel sees probable link between
Pfizer vaccine and myocarditis cases. Reuters, 2021 June
3,
14. https://www.reuters.com/world/middle-east/
israel-sees-probable-link-between-pfizer-vac-
cine-small-number-myocarditis-cases-2021-06-01/
15. Jeyanathan, M., Afkhami, S., & Smaill, F. (2020). Im-
munological considerations for Covid-19 vaccine strate-
gies. Nature Reviews Immunology, 20(10), 615-632.
16. Kupferschmidt, K., & Vogel, G. (2021). Hard choic-
es emerge as link between AstraZeneca vaccine and
rare clotting disorder becomes clearer. 2021 April 11,
https://www.sciencemag.org/news/2021/04/hard-choic-
es-emerge-link-between-astrazeneca-vaccine-and-ra-
re-clotting-disorder-becomes
17. Li, Y., Tenchow, R., & Smoot, J. (2021). A compre-
hensive review of the global effects on Covid-19 vaccine
development. ACS Central Science, 7, 512-533. https://
doi.org/10.1021/acscentsci.1c00120
18. Loza, A.M.M., Holroyd, K.B., & Johnson, S.A. (2021).
Guillain-Barre syndrome in the placebo and active arms
of a Covid-19 vaccine clinical trial. Neurology, 96, 1052-
1054.
19. Lurie, N., Saville, M., & Hatchett, R. (2020). Develop-
ing Covid-19 vaccines at pandemic speed. New England
Journal of Medicine, 382(21): 1969-1973.
20. MacNeil, J.R., Su, J.R., & Broder, K.R. (2021). Updat-
ed recommendations from the Advisory Committee on
Immunization Practices for Use of the Janssen (Johnson
& Johnson) Covid-19 vaccine after reports of thrombosis
with thrombocytopenia syndrome among vaccine recip-
ients – United States. Morbidity and Mortality Weekly
Report CDC, 70(17), 651-656.
21. Matheny, M., Maleque, N., & Channell, N. (2021).
Severe exacerbations of systemic capillary leak syn-
drome after covid-19 vaccination – A case series. An-
nals of Internal Medicine, https://www.acpjournals.org/
doi/10.7326/L21-0250
22. Medicines & Healthcare Products Regulatory Agen-
cy (2021). Research and analysis – Coronavirus vaccine
– weekly summary of Yellow Card reporting. 2021 June
17, https://www.gov.uk/government/publications/coro-
navirus-covid-19-vaccine-adverse-reactions/coronavi-
rus-vaccine-summary-of-yellow-card-reporting
23. Moghadas, S.M., Vilches, T.N., & Zhang, K.
(2021). The impact of vaccination on Covid-19 out-
breaks in the United States. medRxiv, https://doi.
org/10.1101/2020.1127.20240051
24. National Institutes of Health (2021). U.S. clinical
trial results show Novavax vaccine is safe and prevents
COVID-19. 2021 June 14, https://www.nih.gov/news-
events/news-releases/us-clinical-trial-results-show-
novavax-vaccine-safe-prevents-covid-19
25. Norwegian Medicines Agency (2021). Reported sus-
pected adverse reactions to coronavirus vaccines. 2021
June 18, https://legemiddelverket.no/Documents/En-
glish/Covid-19/20210617%20Reported%20suspected%20
adverse%20reactions%20coronavirus%20vaccines.pdf
26. Olliaro, P., Torreele, E., & Vaillant, M. (2021).
25
11. Covid-19 vaccine efficacy and effectiveness – the el-
ephant (not) in the room. Lancet Microbe, https://doi.
org/10.1016/S2666-5247(21)00069-0
27. Patel, S.U., Khurram, R., & Lakhani, A. (2021). Guil-
lain-Barre syndrome following the first dose of the
chimpanzee adenovirus-vectored Covid-19 vaccine,
ChAdOx1. British Medical Journal Case Report, 14,
e242956, https://doi.org/10.1136/bcr-2021-242956
28. Pfizer (2021). Pfizer and BioNTech confirm high
efficacy and no serious safety concerns through up to 6
months following second dose in updated topline analy-
sis of landmark Covid-19 vaccine study.
29. https://www.pfizer.com/news/press-release/press-re-
lease-detail/pfizer-and-biontech-confirm-high-effica-
cy-and-no-serious.
30. Polack, F.P., Thomas, S.J., & Kitchin, N. (2020).
Safety and efficacy of the BNT162b2 mRNA Covid-19
vaccine. New England Journal of Medicine, 383(27),
2603-2615.
31. Ramakrishnan, M., & Subbarayan, P. (2021). Impact
of vaccination in reducing hospital expenses, mortality
and average length of stay among Covid-19 patients- a
retrospective cohort study from India. medRxiv, https://
doi.org/10.1101/2021.06.18.21258798
32. Renoud, L., Khouri, C., & Revol, B. (2021). Associa-
tion of facial paralysis with mRNA Covid-19 vaccines:
A disproportionality analysis using the World Health
Organization pharmacovigilance database. Journal
of American Medical Association Internal Medicine,
https://doi.org/10.1001/jamainternmed.2021.2219
33. Robbins, R., & Mueller, B. (2020). After admitting
mistake, AstraZeneca faces difficult questions about
its vaccine. The New York Times, 2020 November 25,
https://www.nytimes.com/2020/11/25/business/coronavi-
rus-vaccine-astrazeneca-oxford.html.
34. Sadoff, J., Gray, G., & Vandebosch, A. (2021). Safe-
ty and efficacy of single-dose Ad26.COV2.S vaccine
against Covid-19. New England Journal of Medicine,
https://doi.org/10.1056/NEJMoa2101544
35. Shimabukuro, T.T., Kim, S.Y., & Myers, T.R. (2021).
Preliminary findings of mRNA covid-19 vaccine safety
in pregnant persons. New England Journal of Medi-
cine, 384(24), 2273-2282, https://doi.org/10.1056/NEJ-
Moa2104983
36. Starr, T.N., Czudnochowski, N., & Liu, Zhuoming.
(2021). SARS-CoV-2 RBD antibodies that maximize
breadth and resistance to escape. Nature, https://doi.
org/10.1038/s41586-021-03807-6
37. Thanh, L.T., Andreadakis Z., & Kumar, A. (2020).
The Covid-19 vaccine development landscape. Nature
Reviews Drug Discovery, 19(5), 305-306.
38. Thompson, M.G., Burgess, J.L., & Naleway, A.L.
(2021). Prevention and attenuation of Covid-19 with the
BNT162b2 and mRNA-1273 vaccines. New England Jour-
nal of Medicine, 385, 320-329, https://doi.org/10.1056/
NEJMoa2107058
39. Vayne, C., Rollin, J., & Galinat, H. (2021). PF4 immu-
noassays in vaccine-induced thrombotic thrombocyto-
penia. New England Journal of Medicine, 385, 4, https://
doi.org/10.1056/NEJMc2106383
40. Voysey, M., Clemens, S.A.C., & Madhi, S.A. (2021).
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine
(AZD1222) against SARS-CoV-2: an intrim analysis of
four randomised controlled trials in Brazil, South Africa,
and the UK. Lancet, 397(10269), 99-111.
41. Werbel, W.A., Boyarsky, B.J., & Ou, M.T. (2021).
Safety and immunogenicity of a third dose of SARS-
CoV-2 vaccine in solid organ transplant recipients: A
case series. Annals of Internal Medicine, https://doi.
org/10.7326/L21-0282
42. Wise, J. (2021). Covid-19: Should we be worried about
reports of myocarditis and pericarditis after mRNA vac-
cines? British Medical Journal, 373, n1635, http://dx.doi.
org/10.1136/bmj.n1635
| 蕭孟芳醫師
專長臨床熱帶醫學與感染症免疫學 /
目前任職紐西蘭北地區健康局旺格雷醫院 /
英國倫敦大學熱帶醫學博士 /
前國防預防醫學研究所所長 /
前陽明大學熱帶醫學主任
作者
邀稿 | 蔡季君
26